EGFR and glioblastoma: Our data showed significant cytotoxicity by nilotinib plus lapatinib treatment in multi-spheroids of COAD and GBM lines, in primary patient-derived GBMs, and in HCT116 multi-spheroids that recovered from radiation stress induced by 20 Gy-IR, indicating DDR1/BCR-ABL axis with EGFR-ERBB2 targeting as treatment opportunity against chemoradioresistant cancers.